Low-dose naltrexone (LDN) refers to naltrexone hydrochloride administered at roughly one-tenth the dose used for opioid and alcohol addiction treatment. Where standard naltrexone therapy uses 50 mg daily for full opioid receptor blockade, LDN operates in the 1.5-4.5 mg range — a dose sufficient to produce transient receptor blockade lasting approximately 4-6 hours rather than the sustained 24-hour blockade of the full dose. This transient blockade is the entire pharmacological basis for LDN's immune-modulating effects. It is used off-label for a range of autoimmune and chronic inflammatory conditions, prescribed by compounding pharmacies as capsules or liquid formulations.

Mechanism of action

LDN's effects operate through two primary pathways.

The first is the opioid growth factor (OGF) axis. Brief nocturnal blockade of opioid receptors triggers a compensatory upregulation of endogenous opioid production — specifically met-enkephalin (also called opioid growth factor, OGF). OGF acts on the OGF receptor (OGFr) to regulate cell proliferation, including T-cell and B-cell division. This modulates immune surveillance without broadly suppressing or stimulating the immune system. The result is closer to recalibration than amplification.

The second pathway involves Toll-like receptor 4 (TLR4) antagonism. Naltrexone, even at low doses, directly antagonizes TLR4 on microglia and macrophages. TLR4 is a key driver of neuroinflammation and systemic inflammatory signaling. Blocking it reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. This mechanism is independent of opioid receptor effects and likely accounts for much of LDN's benefit in conditions with a neuroinflammatory component such as fibromyalgia and multiple sclerosis.

Dose selection

The effective dose range for LDN is 1.5-4.5 mg. Most patients ultimately stabilize at 4.5 mg, which is the dose used in the majority of clinical trials. However, a subset of patients — particularly those with heightened medication sensitivity or significant neuroinflammation — achieve optimal results at lower doses (1.5-3.0 mg). There is no established benefit to exceeding 4.5 mg; higher doses produce longer receptor blockade that begins to undermine the compensatory endorphin upregulation that drives the therapeutic effect.

LDN is typically prescribed as compounded capsules or as a liquid formulation that allows precise dose adjustments. The liquid form is particularly useful during titration.

Titration schedule

Slow titration is essential. Starting at the full 4.5 mg dose frequently produces vivid dreams, sleep disruption, and headache that cause patients to discontinue unnecessarily. A staged approach:

Weeks 1-2: 1.5 mg nightly. This dose is sub-therapeutic for most patients but establishes tolerance to opioid receptor modulation and identifies highly sensitive individuals who may need to remain at lower doses.

Weeks 3-4: 3.0 mg nightly. Most patients tolerate this step without difficulty. Any vivid dreams or sleep disruption that appeared at 1.5 mg typically resolves by this point.

Week 5 onward: 4.5 mg nightly. This is the target maintenance dose. Assess response over 8-12 weeks before concluding whether LDN is effective.

If side effects are intolerable at any step, hold at the current dose for an additional 2 weeks before attempting to increase. Some practitioners use even finer titration steps (0.5 mg increments) for particularly sensitive patients, which the liquid formulation accommodates well.

Timing

Bedtime dosing (standard): LDN is conventionally taken at bedtime — between 9 PM and midnight — to align the transient opioid receptor blockade with the nocturnal peak of endorphin production that occurs during sleep. The blockade lifts after 4-6 hours, and the rebound surge in endorphin and enkephalin levels coincides with the natural early-morning endorphin peak, amplifying it.

Morning dosing (alternative): A subset of patients experience persistent sleep disruption — vivid dreams, insomnia, or fragmented sleep — that does not resolve with continued use. For these individuals, switching to morning dosing often eliminates sleep-related side effects while preserving clinical benefit. The theoretical concern that morning dosing misses the nocturnal endorphin window has not been validated by outcome differences in clinical practice.

Conditions with clinical evidence

Multiple sclerosis: The most studied indication. A pilot RCT (Cree et al., 2010) showed improved quality of life. Larger observational studies report reduced relapse rates and fatigue scores. Mechanism is likely TLR4-mediated reduction in neuroinflammation.

Crohn's disease: An RCT by Smith et al. (2011) demonstrated a 67% response rate versus 35% placebo, with endoscopic healing in a subset of patients. OGF-OGFr modulation of intestinal epithelial cell proliferation is the proposed mechanism.

Fibromyalgia: Two small RCTs (Younger et al., 2013) showed significant reductions in pain severity (approximately 30% reduction). TLR4 antagonism reducing microglial activation is the leading mechanistic explanation.

Hashimoto's thyroiditis: Limited to case series and observational data showing reductions in thyroid antibody titers (TPO, TG antibodies). No RCT data. Promising but preliminary.

Combination considerations

LDN + Thymosin alpha-1: For patients with autoimmune conditions complicated by immune dysregulation or recurrent infections, combining LDN's immunomodulatory effects with Talpha1's direct T-cell and NK cell support provides complementary coverage. LDN 4.5 mg nightly with Talpha1 1.6 mg SC 2-3 times weekly is a reasonable protocol. No known pharmacological interaction.

LDN + BPC-157: For IBD patients (Crohn's, ulcerative colitis), adding BPC-157 (250-500 mcg SC or oral daily) addresses mucosal healing through growth factor pathways while LDN modulates the underlying immune dysregulation. This targets the condition from two independent angles — immune recalibration plus tissue repair.

Critical contraindication — concurrent opioid use: LDN must not be used by patients currently taking opioid medications, including tramadol, codeine, hydrocodone, oxycodone, morphine, or methadone. Even at low doses, naltrexone will precipitate opioid withdrawal. A minimum washout period of 7-10 days from short-acting opioids (and 14 days from long-acting opioids or methadone) is required before starting LDN.

Monitoring

LDN does not require the intensive bloodwork monitoring associated with many peptide protocols. Recommended tracking includes:

Symptom journal: The most important monitoring tool. Track pain levels, energy, sleep quality, and condition-specific symptoms weekly. LDN effects build gradually over 4-12 weeks.
Inflammatory markers: CRP and ESR at baseline and 12 weeks. Meaningful reductions suggest LDN is engaging anti-inflammatory pathways.
Autoimmune antibody panels: Condition-specific (TPO/TG for Hashimoto's, anti-dsDNA for lupus, etc.) at baseline and 3-6 months. Antibody titer reductions, when they occur, are slow.
Liver function tests: Baseline and 3 months. Standard naltrexone carries a hepatotoxicity warning at 50 mg; at LDN doses this risk is negligible, but baseline LFTs are reasonable practice.

Side effects

Most side effects are transient and resolve within 1-3 weeks:

Vivid dreams: The most commonly reported side effect. Generally resolves after 2-3 weeks. Not harmful but can be disturbing. Slow titration significantly reduces incidence.
Sleep disruption: Insomnia or fragmented sleep during the first 1-2 weeks. Switch to morning dosing if persistent beyond 3 weeks.
Headache: Mild, typically limited to the first week.
Nausea: Uncommon at LDN doses. Usually resolves within days.

Serious adverse effects at LDN doses are rare in the published literature.

Contraindications

Current use of any opioid medication (prescription or illicit)
Acute hepatitis or liver failure (standard naltrexone caution; conservative to apply at LDN doses)
Organ transplant recipients on immunosuppressive therapy (theoretical risk of immune modulation interfering with immunosuppression)
Known hypersensitivity to naltrexone

Evidence assessment

The evidence base for LDN is a mix of well-characterized mechanism, small but positive RCTs, and large bodies of observational and anecdotal data. The OGF-OGFr pathway and TLR4 antagonism are well-documented in preclinical and mechanistic studies. Multiple small RCTs across MS, Crohn's disease, and fibromyalgia show consistent, modest-to-moderate benefits. However, no Phase 3 trial has been completed for any autoimmune indication — largely because naltrexone is a generic drug with no patent incentive for large-scale trials. The safety profile is established from decades of use at higher doses and from extensive off-label prescribing at low doses. LDN represents a case where the mechanistic rationale is strong, the safety margin is wide, and the clinical evidence is positive but underpowered. Most integrative practitioners consider it a reasonable intervention with a favorable risk-benefit ratio, while acknowledging the absence of definitive large-scale efficacy data.